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Abstract 48 
Among the 1700 mutations reported in the cystic fibrosis transmembrane conductance 49 
regulator (CFTR) gene, a missense mutation, p.Ser1235Arg is a relatively frequent 50 
finding. To clarify its clinical significance, we collected data from 104 subjects 51 
heterozygous for the mutation p.Ser1235Arg from the French CF network, addressed 52 
for various indications including classical CF, atypical phenotypes or carrier screening 53 
in subjects with or without a family history. Among them, twenty-six patients (five 54 
having CF, ten CBAVD -Congenital Absence of the Vas Deferens- and eleven with CF-55 
like symptoms) and fourteen healthy subjects were compound heterozygous for a 56 
second CFTR mutation. An exhaustive CFTR gene analysis identified a second 57 
mutation in cis of p.Ser1235Arg in all CF patients and in 81.8% CBAVD patients. 58 
Moreover, epidemiological data from more than 2100 individuals found a higher 59 
frequency of  p.Ser1235Arg in the general population than in CF or CBAVD patients. 60 
These data, added to the fact that in silico analysis and functional assays suggest a 61 
benign nature of this substitution gives several lines of evidence against an association 62 
of p.Ser1235Arg with CF or CBAVD.  63 
 64 
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Introduction 65 
Cystic Fibrosis (CF, MIM≠219700), one of the most frequent life-shortening 66 
recessively inherited diseases, is caused by alterations in the CFTR gene (Cystic 67 
Fibrosis Transmembrane Conductance Regulator; MIM≠602421), that result in loss or 68 
impairment of CFTR-mediated ion transport across epithelial cell membrane. The 69 
clinical expression and severity of CF are highly variable. Severe phenotypes are 70 
usually associated with high concentrations of sweat chloride, early onset of pancreatic 71 
insufficiency (PI), meconium ileus at birth and severe lung disease, whereas mild 72 
phenotypes are associated with lower sweat chloride concentrations, pancreatic 73 
sufficiency (PS) and variable lung disease. Mutations in the CFTR gene are also 74 
involved in atypical phenotypes1 such as CBAVD (Congenital Bilateral Absence of the 75 
Vas Deferens; MIM # 277180), mild pulmonary diseases or ICP (Idiopathic Chronic 76 
Pancreatitis).  77 
Since the cloning of the CFTR gene, a wide spectrum of molecular abnormalities 78 
(more than 1700 mutations, variants or polymorphisms) has already been reported to the 79 
Cystic Fibrosis Genetic Analysis Consortium (http://www.genet.sickkids.on.ca/cftr/). 80 
However, a clear statement on the pathogenicity of a mutation is difficult to obtain, in 81 
particular for missense mutations 2,3. Moreover, the existence of at least two mutations 82 
or sequence variations on the same allele, named complex alleles, complicates genetic 83 
counseling 4-11. p.Ser1235Arg (3837T>G or c.3705T>G), initially reported by Cuppens 84 
et al. 12 with a second mutation on the same allele, p.Gly628Arg, is located in a poorly 85 
conserved region in the second nucleotide binding fold (NBF2). Earlier reports failed to 86 
establish a clear impact of p.Ser1235Arg on the phenotype severity 13-16. The aim of this 87 
study was to determine whether we should consider p.Ser1235Arg as a possible CF-88 
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associated mutation or reclassify it as a neutral polymorphism. Thus, we implemented a 89 
large collaborative study to repertory the patients or individuals bearing the 90 
p.Ser1235Arg mutation from nine French laboratories and compared their phenotype, 91 
genotype and associated CFTR haplotypes. To predict the potential effect of this 92 
sequence variation on the CFTR protein, in silico analyses using various programs and 93 
functional studies were performed. Here, we gather lines of evidence that p.Ser1235Arg 94 
should be no longer considered as a CF mutation. 95 
 96 
Materials and Methods 97 
Patients and individuals 98 
Data were collected from one hundred and four subjects heterozygous or compound 99 
heterozygous for the p.Ser1235Arg mutation registered from the French CF network of 100 
molecular genetics laboratories. Among them, sixty-seven were referred for diagnosis: 101 
classical CF (six unrelated patients), CAVD (ten individuals with bilateral and one with 102 
unilateral Congenital Absence of the Vas Deferens), fetal suspicion of CF (eight fetuses 103 
with abnormal ultrasound signs of bowel anomalies) and forty-two individuals 104 
presenting CF-related symptoms (according to the International Classification of 105 
Disease (ICD) in the section “Cystic Fibrosis and Related Disorders” [Meeting report, 106 
2002]) with normal or borderline sweat chloride values including genital (five 107 
individuals), respiratory (twenty-three individuals) or digestive (fourteen individuals) 108 
symptoms. Thirty-seven healthy subjects were referred for carrier screening including 109 
fourteen individuals with a positive family history and twenty-three partners of CF 110 
patients or carriers. Written consents to the genetic study were obtained from the 111 
patients and/or their family and from healthy subjects.  112 
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 113 
Molecular epidemiological study 114 
To evaluate the p.Ser1235Arg frequency in the general population, we screened for 115 
2114 samples: 929 anonymized dried-blood spot of neonates presenting positive or 116 
negative IRT (Immuno Reactive Trypsinogen) at day 3 obtained from the center for 117 
neonatal screening in Montpellier, South of France and 1185 genomic DNA from CF 118 
patient's or relative’s partners from the cohort of the Southern France (Laboratory of  119 
molecular genetics of Montpellier) or from the cohort of the Northern France 120 
(Laboratory of  molecular genetics of Lille).  121 
 122 
Mutation Nomenclature 123 
Gene variants at the protein level were named as recommended in the Human Genome 124 
Variation Society web page (http://www.hgvs.org/mutnomen/). For variations described 125 
at the nucleotide level, the A of the ATG translation start codon was numbered as +133 126 
in accordance with the current CFTR gene numbering based on cDNA sequence 127 
(GenBank NM_000492.3) and on the CF mutation database. These variations were also 128 
given in parentheses following the approved nomenclature format (A of the ATG 129 
translation start codon as +1). 130 
 131 
CFTR Genotype Analysis 132 
Genomic DNA 133 
Genomic DNA was prepared from peripherical blood leukocytes or from amniotic 134 
liquid according to standard protocols. Patients: The CFTR gene coding and flanking 135 
regions were analyzed by PCR amplification followed by DGGE (Denaturing Gel 136 
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Gradient Electrophoresis), SSCA (Single Strand Conformation Analysis), DHPLC 137 
(Denaturing High Performance Liquid Chromatography) or heteroduplex analysis 138 
followed by sequencing each abnormal pattern detected to characterize the variants. If 139 
p.Ser1235Arg was found alone, a screening for large CFTR rearrangements was 140 
performed using a semi-quantitative fluorescent multiplex PCR assay. Patients' 141 
relatives: A screening for the familial mutations was implemented. Patients' partners: 142 
In primary screening, five to twelve exons, including exons 13 and 19, were screened by 143 
laboratories. 144 
To determine the haplotype associated with the p.Ser1235Arg allele, 6 microsatellite 145 
markers (IVS1(CA), IVS8(CA), IVS8(TG)m,  IVS8T(n), IVS17b(TA), IVS17b(CA)) 146 
and one biallelic marker (p.Met470Val or 1540A>G( c.1408A>G)) were investigated. 147 
Guthrie cards 148 
Spots of 3 mm diameter, punched from anonymized cards, were distributed in 96-well 149 
plates and DNA was extracted using methanol extraction17. p.Ser1235Arg was screened 150 
for using DHPLC  technology and each abnormal pattern was confirmed by sequencing 151 
analysis. 152 
 153 
Computer-assisted analysis 154 
To predict the potential pathogenicity of p.Ser1235Arg, we used PolyPhen® and 155 
SIFT® softwares. The PolyPhen® program (http://coot.embl.de/PolyPhen/) is based on 156 
the sequence homology and the mapping of the substitution site to known protein 3-157 
dimensional structures. Results are given as "benign", "possibly damaging", "probably 158 
damaging", or "unknown". The SIFT® program (http://blocks.fhcrc.org/sift/) uses 159 
sequence homology to predict whether an amino acid substitution will affect protein 160 
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function and hence, potentially alters phenotype. Results are reported as "deleterious or 161 
not". Consequences on the splicing machinery were evaluated by Human Splicing 162 
Finder tool (http://www.umd.be/HSF). This program integrates all available matrices to 163 
identify ESE, ESS, ISE and ISS motifs: ESE Finder 18, RESCUE ESE 19, Silencer 164 
motifs from Sironi et al. 20, ESS decamers from Wang et al. 21 and new algorithms to 165 
calculate the consensus values of potential splice sites and search for Branch points. To 166 
gain some insight into the potential effect of the p.Ser1235Arg mutation from a 167 
structural point of view, we used the experimental structures of MJ0796 (in complex 168 
with ATP, pdb identifier 1l2t) as template for modeling as previously described by 169 
Eudes et al. 22. The MJ0796 structure was visualized with MBT SimpleViewer software. 170 
The alignment of sequences of the two CFTR NBDs, other ABC transporters family and 171 
MJ0796 was obtained by ClustalW program and visualized using Jalview 2.3 tools. 172 
 173 
In vitro functional studies 174 
CFTR expression plasmids, Site-Directed Mutagenesis, minigene constructs and 175 
cells 176 
A plasmid expressing the human CFTR gene was constructed by placing the full-length 177 
CFTR cDNA coding sequence obtained from pTG5985 plasmid, a gift from Transgene 178 
SA, in the pcDNA3(+) expression vector. The p.Ser1235Arg mutation was inserted into 179 
the pcDNA3-CFTR vector by site-directed mutagenesis using QuickChange® II Site-180 
Directed Mutagenesis Kit (Stratagene) according to the manufacturer’s instructions.  181 
The human CFTR genomic region encompassing the exon 19 with the flanking intronic 182 
sequences, was amplified from a patient heterozygous for the p.Ser1235Arg using 183 
primers FOR 5’AATTCTGGAGCTCGAGCAGGCCTATACAGAGCCCATT-3’ and 184 
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REV 5’ CTCTTAATTTGCTAGCCATTTTCAAGATGGGAAATCTAAAACA-3’ 185 
(which introduce NheI and XhoI sites in the PCR product). After enzymatic digestion, 186 
the PCR product was subcloned into the XhoI/NheI digested pSPL3 plasmid, kindly gift 187 
by Dr. S. Tuffery-Giraud (Laboratory of Molecular Genetics, Montpellier, France).  One 188 
clone containing the wild-type allele and one with the mutation were retained for 189 
expression experiments. All plasmid constructs were fully sequenced.  190 
Beas2B, a human bronchial epithelial cell line expressing CFTR and the monkey kidney 191 
fibroblast cells COS-7, which does not express endogenous CFTR, were cultured as 192 
previously described 23.  Cells were seeded at a density of 200, 000 cells/2 ml of 193 
medium in 6-well dishes.  After 24h, cells were transfected with Polyfect transfection 194 
reagent (Qiagen, France) according to the manufacturer’s recommendations. All 195 
experiments were repeated at least twice. 196 
RNA extraction and RT-PCR 197 
Total RNA was extracted using RNeasy Plus kit (Qiagen, France). Reverse transcription 198 
was performed with 1 µg of total RNA as previously described 23. 1 μl of the cDNA 199 
synthesis reaction was used for PCR analyses using a mixture of 10 pmol of both 200 
SD6/SA2 primers and β-actin primers, 0.5 U of Taq DNA polymerase (New England 201 
Bio Labs Inc) and 10 mM of dNTPs in a 25 μl volume. Amplification was performed 202 
with an initial denaturation step at 94°C for 5 min, 35 cycles of 94°C 30s, 57°C 30s, 203 
72°C 90s, followed by a final extension step 72°C 7 min. PCR products were visualized 204 
on 1.5 % agarose gel. Each PCR product was purified and fully sequenced. 205 
Whole cells extracts and Western-Blot 206 
Whole cells extracts from 6-well dishes were extracted and resuspended in Laemmli 207 
buffer. Proteins were separated by SDS-PAGE in a 5% acrylamide gel, transferred in a 208 
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PVDF membrane and immunoblotted with antibody against CFTR (MM13-4 from 209 
Millipore). 210 
 211 
Statistical analysis 212 
Statistical analyses were performed using Instat® software. Chi-square test was used to 213 
compare differences between general population vs CF patients or general population vs 214 
CBAVD patients. P-values < 0.05 were considered to indicate statistical significance. 215 
 216 
Results 217 
Genotype/phenotype description of individuals carrying p.Ser1235Arg 218 
Among 104 subjects from 91 unrelated families reported by the nine French 219 
laboratories, 6 patients are affected with classical CF (Table 1A). Five of them were 220 
referred for severe disease with diagnosis before one year, positive sweat test, 221 
pancreatic insufficiency and persistent respiratory infections, and one had a mild 222 
phenotype with a borderline sweat test. Complete scanning of the 27 exons and their 223 
boundaries identified a second mutation on the same allele for all of them: 1) 224 
p.Arg785X, located in exon 13, predicting a truncated protein; 2) 875+1G>A 225 
(c.743+1G>A) affecting the highly conserved splice donor site sequence; 3) the 226 
(TG)13(T)5 allele which promotes CFTR exon 9 skipping in humans 24-26.  227 
Ten patients were referred for CBAVD (Congenital Bilateral Absence of Vas 228 
Deferens) and one for CUAVD (Congenital Unilateral Absence of Vas Deferens) 229 
without renal anomalies. The (TG)13(T)5 allele was found in 9 subjects with 230 
p.Ser1235Arg (Table 1A). Of these, eight were compound heterozygous for 231 
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p.Phe508del, and two for mutations associated with CF-related diseases3,27, 232 
[p.Arg117His;T7] and p.Arg1070Trp (http://www.genet.sickkids.on.ca/cftr/).  233 
 Among 42 patients with monosymptomatic disease carrying p.Ser1235Arg (Table 234 
1A), eight cases (19%) were compound heterozygotes, seven for a severe mutation and 235 
one for the intronic variant 406-6T>C (c.274-6T>C). Of these, five harbored the 236 
(TG)13(T)5 allele associated in cis with p.Ser1235Arg. Thirty-four individuals (81%) 237 
were heterozygous for p.Ser1235Arg: 5 with reduced sperm quality, 16 with 238 
sinopulmonary problems such as bronchiectasis, asthma, nasal polyposis, chronic 239 
obstructive pulmonary disease, and 13 with digestive symptoms (meconium ileus at 240 
birth, pancreatitis, liver disease). One of them, referred for bronchitis and recurrent 241 
infections without bronchiectasis, had a positive sweat test (102 mmol/l).  242 
 Eight fetal samples were referred for risk calculation in the cohort of 243 
hyperechogenic fetal bowel. Among them, five carried only p.Ser1235Arg and were 244 
considered simple heterozygote because extensive scanning did not reveal a second CF 245 
mutation 28. Three cases were compound heterozygous for another mutation. In the first 246 
case, a moderate hyperechogenicity was detected at 22 weeks’ pregnancy, which 247 
decreased at 31. The fetus harbored the p.Phe508del mutation on the other allele and 248 
parents decided to continue pregnancy. The second carried the rare missense mutation 249 
p.Val920Met and depressed values of digestive enzymes were observed at 17 weeks of 250 
pregnancy. In the last case, the fetus carried the complex allele 251 
[p.Gly576Ala ;p.Arg668Cys], considered as a mild mutation involved in CBAVD or 252 
disseminated bronchiectasis phenotypes in adults 29-31. Although the fetus presented 253 
hyperechogenic fetal bowel, the parents were reassured regarding the risk of classical 254 
CF. Unfortunately, no data were available on the outcome of these pregnancies. 255 
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Among 37 individuals tested for cascade carrier screening, 14 were compound 256 
heterozygous for p.Ser1235Arg and another CFTR mutation (Table 1B), all being 257 
relatives of patients or carriers. Of these, twelve harbored in trans a CF-causing 258 
mutation. No symptom of CF was notified although sweat test was not performed. 259 
Notably, cases 4 and 5 were two fertile fathers carrying a Class I mutation (severe) 260 
associated in trans of p.Ser1235Arg.  261 
 262 
Frequencies of p.Ser1235Arg in the general, CF and CBAVD French populations 263 
Thirty-two p.Ser1235Arg alleles were detected in 2114 subjects of the general 264 
population representing an allelic frequency of 0.76% (Table 2). None of them had the 265 
p.Arg785X mutation. This allele frequency was compared with those of patients 266 
collated in a French study affected with CF (8/7420 alleles) or CBAVD (7/1626 alleles), 267 
0.11% and 0.43%, respectively 32. By χ2 statistical analysis, the p.Ser1235Arg allelic 268 
frequency is significantly higher in the general population than in CF patients (0.76% 269 
vs. 0.11%, p< 0.001) but not statistically different from the CBAVD group (0.76% vs. 270 
0.43%, p> 0.1). Recently, six CF patients were re-analyzed. Among them, five with 271 
severe disease, harbored the p.Arg785X mutation, while another presenting a mild 272 
phenotype had the complex allele [p.Ser1235Arg;T5]. When the p.Ser1235Arg 273 
frequencies in CF, CBAVD and the general population are compared to frequencies of 274 
p.Phe508del (Table 2), it appears that p.Ser1235Arg is as frequent as p.Phe508del 275 
(p=0.91) in the general population (respectively 0.76% vs. 0.82%); however, its 276 
implication in classical CF is significantly different (0.11% vs. 67.2% (p<0.0001) and 277 
2.86% (p<0.0001) respectively). 278 
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 279 
p.Ser1235Arg haplotype backgrounds  280 
Haplotypic markers and familial segregation were completed in thirty-six cases 281 
(Table 3). The analysis of haplotypes based on four intragenic CFTR markers 282 
(IVS1(CA), IVS8(CA), M470V, IVS17b(CA)) revealed that p.Ser1235Arg is always 283 
present on the same haplotype 26-17-M-13. This haplotype associated with the 284 
polyvariant (TG)12(T)7 represents 77.8% of cases. Only the IVS17b(TA) microsatellite 285 
marker shows a large variability in this study ranging from 7 to 44 repeats. However, 286 
three complete haplotypes differing only by one repeat in the IVS17b(TA) (35, 36 and 287 
37) accounted for more than 63% of the cases. The p.Arg785X found in CF patients in 288 
cis of the p.Ser1235Arg occurs on a single haplotype 26-17-12-7-M-35-13. The 289 
complex allele [p.Ser1235Arg;(TG)13(T)5] characteristic of CBAVD, was also found to 290 
be carried on a unique haplotype (26-17-13-5-M-33-13).  291 
 292 
In silico predictions and functional impact on the CFTR protein  293 
We evaluated the degree of conservation of  serine 1235 residue using alignment 294 
of the Nucleotide Binding Domains of the human CFTR with those of ABC 295 
transporters, whose the CFTR belongs (Figure 1A). The results show that the serine 296 
1235 is poorly conserved in the ABC transporter family, suggesting that amino acid 297 
change in this position is possible. Serine 1235 residue located after a β strand is not 298 
involved in anchor or structural points 33. The analysis of its position on the 3D 299 
structure of MJ0796 (Figure 1B) previously used as template for modeling the CFTR 300 
NBDs 22, points that the Serine 1235 is located on the exterior surface of the NBD2. 301 
Therefore, this amino acid does not participate to the NBD1/NBD2 heterodimer 302 
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formation and to the ATP binding and hydrolysis. The limited effect of this amino acid 303 
change was confirmed using SIFT® and PolyPhen® programs. To evaluate the 304 
functional impact of the mutation on the CFTR maturation, we performed Western-blot 305 
analysis on whole cell extracts from COS-7 cells transfected with either wild-type or the 306 
p.Ser1235Arg constructs (figure 1C). The results show the presence of the fully-307 
glycosylated CFTR protein (Band C) with the p.Ser1235Arg construct, suggesting that 308 
the maturation of the pSer1235Arg-CFTR protein is not altered. These results suggest 309 
that p.Ser1235Arg has no functional impact on the CFTR protein.  310 
 311 
Functional impact of the pSer1235Arg on the splicing 312 
According to the Splicing Sequences Finder tools 34, p.Ser1235Arg does not 313 
seem to impact the splicing of CFTR transcript. To verify this prediction, we used a 314 
minigene-based approach. Constructs containing the wild type and mutant CFTR exon 315 
19 and the intron-exon boundaries were inserted in the pSPL3 vector (figure 2A). After 316 
transfection in Beas2B cell line, RNAs were extracted and subjected to RT-PCR. As 317 
shown in figure 2B, compared to the wild-type, the presence of the pSer1235Arg 318 
alteration does not modify the exon 19 inclusion in the mRNA. Together, these data 319 
suggest that pSer1235Arg has no effect on the CFTR mRNA splicing. 320 
 321 
Discussion 322 
Since its initial description in 1993, the clinical significance of the p.Ser1235Arg 323 
mutation remains unclear. This ignorance makes genetic counseling very difficult, 324 
especially in the context of prenatal diagnosis. Through genotype/phenotype analysis of 325 
patients or individuals carrying p.Ser1235Arg, analyzed by the French network and 326 
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functional analysis, we present several lines of evidence that argue against an 327 
association of pSer1235Arg with CF or CBAVD although a partial penetrance of 328 
p.Ser1235Arg could not be ruled out. 329 
 First, the presence of a complex allele [p.Ser1235Arg;class I mutation] in trans 330 
of a severe mutation in five patients presenting severe disease (Table 1A) strongly 331 
suggests that p.Ser1235Arg alone cannot be considered as a CF-causing mutation. 332 
Moreover, among the eleven patients referred for CAVD, nine are compound 333 
heterozygous for a mutation and the complex allele [p.Ser1235Arg;(TG)13(T)5]. The 334 
(TG)13(T)5 allele without the contribution of p.Ser1235Arg is sufficient to result in 335 
male infertility or in mild phenotypes24,25,35. Among the two patients with p.Ser1235Arg 336 
as single allele, one has the mutation p.Phe508del in trans while no other mutation was 337 
identified in the second one. The possibility of mutations in intronic regions 338 
undetectable by our methods cannot be excluded.  339 
Second, we present 14 asymptomatic individuals (Table 1B), of whom 12 340 
carried a severe and two a mild mutation in trans. Three, carrying the complex allele 341 
[p.Ser1235Arg; (TG)13(T)5], are sisters or brother of CBAVD or CUAVD patients and 342 
no respiratory or digestive symptom was reported. In females, allele (T)5 has been 343 
shown to have a low penetrance 36 while no urogenital data was available for the male 344 
because of absence of parental project. Three adult males are compound heterozygous 345 
for p.Ser1235Arg and a severe mutation; two (cases 4 and 5) are biological fathers of 346 
CF children and transmitted the severe mutation. Case 7 to 11 are patients’ mothers or 347 
relatives with no evidence of CF symptoms. Cases 12 and 13 are non-symptomatic 348 
sister and first-cousin of a patient with respiratory symptoms whose CF diagnostic 349 
could be discussed because symptoms are close to asthma.  350 
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Third, the frequency of the p.Ser1235Arg in the general population (Table 2) is 351 
higher than in CF and CBAVD patients, in accordance with previous reports 14,37, and is 352 
close to the p.Phe508del frequency (0.82%). By contrast, in CF or CBAVD groups, the 353 
p.Ser1235Arg frequency is significantly lower than p.Phe508del.  354 
In the functional point of view, results from alignment show that this residue is 355 
poorly conserved and occurs in a region not implicated in known CFTR functions. 356 
Moreover, in silico predictions suggest that this nucleotide change is not critical for the 357 
mRNA splicing and the CFTR function.  These data are confirmed by functional 358 
studies, which showed that p.Ser1235Arg does not alter the CFTR mRNA correct 359 
splicing and the protein maturation. These data are consistent with previous functional 360 
study of this locus in combination with alleles found at p.Met470Val and p.Gly628Arg 361 
loci 13. Wei et al. demonstrated that the p.Ser1235Arg CFTR protein does not cause 362 
change in the chloride transport activity. Besides, the p.Gly628Arg/p.Ser1235Arg 363 
mutant protein induces a significantly lower cAMP dependent chloride transport 364 
activity than the p.Gly628Arg mutant protein, showing the major importance of genetic 365 
background, particularly for missense mutations.  366 
 367 
In a second step, we determined the haplotypes linked to p.Ser1235Arg and 368 
found the same haplotype in 72.4% of cases. Only the IVS17b(TA) marker presents a 369 
large variability although three haplotypes, deriving one from the other by addition or 370 
deletion of one dinucleotide (35, 36 or 37 repeats), represent more than 55% of the 371 
alleles. Besides, IVS1(CA) 26, a rare allele in the European populations (4.2% vs 80% 372 
for alleles 22, 23 ad 24) 38, is strictly linked to p.Ser1235Arg. In CBAVD patients, the 373 
haplotype 26-17-13-5-M-33-13 was found in 85.7% of p.Ser1235Arg alleles. This data 374 
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suggests the further change of the (TG)12(T)7 to (TG)13(T)5 on a chromosome bearing 375 
the alteration p.Ser1235Arg on a background IVS17b(TA)33. Together, this data 376 
suggests that p.Ser1235Arg could derive from a founding event and haplotypes 377 
differing by a single microsatellite could depend on slippage phenomena, as already 378 
proposed 39. 379 
 380 
In conclusion, there are now strong lines of evidence against a severe deleterious 381 
effect of p.Ser1235Arg and its association with classical CF or CBAVD disease. 382 
However, a partial penetrance and/or the presence of other sequence alterations in non-383 
screened regions particularly in patients with atypical or mild symptoms of cystic 384 
fibrosis 27,40,41 cannot be ruled-out. This data highlights the importance of searching for 385 
a complex allele whenever p.Ser1235Arg is identified. The absence of clinical effects in 386 
healthy individuals compound heterozygous for the p.Ser1235Arg and another severe 387 
mutation is helpful to provide adequate genetic counseling to the families with regard to 388 
its transmission in offspring.  389 
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Titles and legends to figures  573 
Figure1:  Structural and processing impact of p.Ser1235Arg mutation on the CFTR 574 
protein.  575 
A: Conservation of residues close to Ser1235 (blue square) in the two NBD sequences 576 
of human CFTR and other ABC transporters. Positions always occupied by 577 
hydrophobic amino acids (V, I, L, M, F, Y, W) are shaded blue. Conserved glycine and 578 
lysine are colored in orange and in red, respectively.  579 
B: Localization of the serine 1235 on the 3D-modelization of the NBD1/NBD2 580 
heterodimer . 581 
C: COS-7 cell line were transfected with either wild-type or p.Ser1235Arg CFTR 582 
constructs. 48 hours post-tranfection, whole-cell proteins were extracted and subjected 583 
to a Western-blot analysis. Experiments were repeated three times. 584 
 585 
Figure 2: Functional impact on the CFTR mRNA splicing 586 
A:  Schema of the minigene constructs in pSPL3 vector. The exon 19 and exon-intron 587 
junctions were inserted in the multiple cloning site of the pSPL3 vector between the 588 
exon A and B from the β-globin by PCR-restriction.  589 
B: RT-PCR analysis of mRNA of cell expressing Wild-Type42 or 590 
p.Ser1235Arg(S1235R) constructs. BeaS2B cells were transfected with either empty, 591 
wild-type or p.Ser1235Arg pSPL3 vector. After 48 hours, total RNA were extracted and 592 
cDNA were synthetized.  PCR was performed using SA2 and SD6 primers amplifying 593 
the region between exon A and B. On the right, the composition of each transcript was 594 
indicated. Each experiment was repeated at least three times. 595 
596 
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Table 1A Genotype and phenotype of CF, CBAVD and CF-like patients carrying the 597 
p.Ser1235Arg mutation. 598 
Genotype phenotype No of subjectsallele 1 allele 2 
p.Ser1235Arg;p.Arg785X p.Phe508del  severe CF  2 
p.Ser1235Arg;p.Arg785X NA 1 severe CF  1 
p.Ser1235Arg;875+1G>A 
(c.743+1C>A) 3629delT (c.3497delT)  severe CF  1 
p.Ser1235Arg;p.Arg785X p.Gly542X  severe CF  1 
p.Ser1235Arg;(TG)13(T)5 p.Gly551Asp mild CF 1 
p.Ser1235Arg;(TG)13(T)5 p.Phe508del CBAVD 6 
p.Ser1235Arg;(TG)13(T)5 p.Arg1070Trp CBAVD 1 
p.Ser1235Arg;(TG)13(T)5 p.Arg117His; (T)7 CBAVD 1 
p.Ser1235Arg p.Phe508del CBAVD 1 
p.Ser1235Arg - CBAVD 1 




p.Ser1235Arg - genital symptoms 5 
p.Ser1235Arg - respiratory symptoms 16 
p.Ser1235Arg;(TG)13(T)5 p.Phe508del respiratory symptoms 2 
p.Ser1235Arg 406-6T>C (c.274-6T>C) respiratory symptoms 1 
p.Ser1235Arg p.Tyr1092X respiratory symptoms 1 
p.Ser1235Arg p.Glu831X respiratory symptoms 1 
p.Ser1235Arg p.Gln493X respiratory symptoms 1 
p.Ser1235Arg p.Ile507del respiratory symptoms 1 
p.Ser1235Arg - digestive symptoms 13 
p.Ser1235Arg p.Gly542X digestive symptoms 1 
p.Ser1235Arg - hyperechogenic fetal bowel 5 
p.Ser1235Arg p.Arg668Cys;p.Arg576Ala hyperechogenic fetal bowel 1 
p.Ser1235Arg p.Val920Met hyperechogenic fetal bowel 1 
p.Ser1235Arg p.Phe508del hyperechogenic fetal bowel 1 
1 NA: Not Available ; We could only test the mother and an healthy sister (the patient 599 
was deceased and the father’s DNA was not available)600 
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 601 
Table 1B Genotype and familial history of asymptomatic individuals carrying the 602 
p.Ser1235Arg mutation. 603 
Case # Genotype Familial information 
allele 1 allele 2 
1 p.Ser1235Arg;(TG)13(T)5 p.Phe508del brother of CUAVD (no parental project) 
2 p.Ser1235Arg;(TG)13(T)5 p.Phe508del sister of CUAVD  
3 p.Ser1235Arg;(TG)13(T)5 p.Arg1070Trp sister of CBAVD  
4 p.Ser1235Arg p.Gly542X 
father of CF [p.Phe508del]+ [p.Gly542X] 
and healthy children [p.Ser1235Arg]+ 
[(TG)11(T)5] 
5 p.Ser1235Arg p.Gln493X father of CF [p.Phe508del]+[p.Gln493X]  
6 p.Ser1235Arg p.Phe508del uncle of CF (no parental project) 
7 p.Ser1235Arg p.Phe508del mother of CF [p.Phe508del]+[1717-1G>A (c.1585-1G>A)] 
8 p.Ser1235Arg 2347delG (c.2215delG) mother of CF [p.Phe508del]+[2347delG]  
9 p.Ser1235Arg (TG)11(T)5 mother of non CF fetus with hyperechogenic fetal bowel [p.Phe508del]+[(TG)11(T)5]  
10 p.Ser1235Arg p.Phe508del sister of CBAVD  
11 p.Ser1235Arg p.Phe508del sister of CBAVD  
12 p.Ser1235Arg p.Glu831X sister of CF-like patient 
13 p.Ser1235Arg p.Phe508del first-cousin of CF-like patient  
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  607 
Table 2: Comparison of the allelic frequencies of p.Ser1235Arg and p.Phe508del in the 608 
general population, CF and CBAVD patients.  609 
  Populations  Significance 
(p-values) 

















p.Phe508del  0.82% 
(n=1950) 
67.2% 21.6%  S (p< 
0.05) 
S (p< 0.05) 





















   
n: number of unrelated tested chromosomes. S: Significant difference; NS: No 610 
Significant difference. P-values significant at <0.05 611 
  612 
613 
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 Table 3: CFTR haplotypes for 36 fully haplotyped p.Ser1235Arg chromosomes from 614 
CF, CBAVD patients, ruled-out CF (including CF-like symptoms and Fetal echogenic 615 





- IVS8(T)n Mutation in cis 
IVS17b(TA
) n % 





(c.743+1C>A) 36 1 2.8
  None 33 1 2.8
   35 5 
13.
8 
   36 9 25 
   37 4 
11.
1 
   38 1 2.8
   40 1 2.8
   44 1 2.8
   7 1 2.8
      
  13-5   33 8 
22.
2 
  617 
 618 
 619 
 620 
 621 
 622 


